2022
Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study
BRETSCHNEIDER, Maxi Pia, Jan KLÁSEK, Martina KARBANOVÁ, Patrick TIMPEL, Sandra HERRMANN et. al.Základní údaje
Originální název
Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study
Autoři
BRETSCHNEIDER, Maxi Pia (276 Německo), Jan KLÁSEK (203 Česká republika), Martina KARBANOVÁ (203 Česká republika, domácí), Patrick TIMPEL (276 Německo), Sandra HERRMANN (276 Německo) a Peter E. H. SCHWARZ (276 Německo)
Vydání
Nutrients, Basel, MDPI, 2022, 2072-6643
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30304 Public and environmental health
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.900
Kód RIV
RIV/00216224:14110/22:00125808
Organizační jednotka
Lékařská fakulta
UT WoS
000794653000001
Klíčová slova anglicky
diabetes mellitus type 2; self-management; digital health; HbA1c; lifestyle intervention; digital intervention; mHealth
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 1. 2023 10:56, Mgr. Tereza Miškechová
Anotace
V originále
The aim of this study was to provide preliminary evidence on the impact of the digital health application Vitadio on improving glycemic control in patients with type 2 diabetes mellitus. This was a 3-month, prospective, multicenter, open-label trial with an intraindividual control group. Participants received a digital lifestyle intervention. HbA1c levels were observed at 3 time points: retrospectively, at 3 months before app use; at baseline, at the start of usage; and 3 months after the start of use. In addition, changes in other metabolic parameters (fasting glucose, body weight, and waist circumference), patient reported outcomes (quality of life, self-efficacy, and depression), and data generated within the app (frequency of use, steps, and photos of meals) were evaluated. Repeated measures analysis of variance with the Bonferroni correction was used to assess the overall difference in HbA1c values between the intervention and the intraindividual control group, with p < 0.05 considered significant. Participants (n = 42) were 57 +/- 7.4 years old, 55% male, and with a mean baseline HbA1c of 7.9 +/- 1.0%. An average HbA1c reduction of -0.9 +/- 1.1% (p < 0.001) was achieved. The digital health application was effective in significantly reducing body weight (-4.3 +/- 4.5 kg), body mass index (-1.4 +/- 1.5 kg/m(2)), waist circumference (-5.7 +/- 15 cm), and fasting glucose (-0.6 +/- 1.3 mmol/L). The digital therapy achieved a clinically meaningful and significant HbA1c reduction as well as a positive effect on metabolic parameters. These results provide preliminary evidence that Vitadio may be effective in supporting patient diabetes management by motivating patients to adopt healthier lifestyles and improving their self-management.